Stocks · News reference
Tenaya Therapeutics Q2 EPS $(0.20) Misses $(0.05) Estimate, Sales $1.110M Miss $10.000M Estimate
Tenaya Therapeutics (NASDAQ:TNYA) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate of $(0.05) by 300 percent. This is a 42.86 percent decrease over losses of $(0.14) per share
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
FDA Grants Regenerative Medicine Advanced Therapy Designation To Tenaya Therapeutics’ TN-401, Gene Therapy Candidate For Treatment Of PKP2-Associated Arrhythmogenic Right Ventricular Cardiomyopathy
RMAT Designation Supported by Positive Interim Data from RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 which Demonstrated Reduced Arrhythmia Burden Additional Data and Updates on Regulatory Discussions Anticipated in 4Q